Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C514S013800, C514S014800, C530S303000, C530S326000, C435S069400
Reexamination Certificate
active
06933274
ABSTRACT:
The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.
REFERENCES:
patent: 5597796 (1997-01-01), Brange
patent: 6197926 (2001-03-01), Gaur et al.
patent: 6562942 (2003-05-01), Gaur et al.
patent: WO 96/04307 (1996-02-01), None
patent: WO 97/02043 (1997-01-01), None
patent: WO 99/42482 (1999-08-01), None
Daniel and Wegmann, “Intranasal Administration of Insulin Peptide B: 9-23 Protects NOD Mice from Diabetes,”Annals of the New York Academy of Sciences 778: 371-372, 1996.
Daniel and Wegmann, “Protection of nonobese diabetic mice from diabetic by intranasal or subcutaneous administration of insulin peptide B-(9-23),”Proc. Natl. Acad. Sci. USA 93: 956-960, Jan. 1996.
Gattner et al., “The Preparation of Two Mutant Forms of Human Insulin, Containing Leucine in Position B24 or B25, by Enzyme-Assisted Synthesis,”Hoppe-Seyler's Z. Physiol. Chem. 361: 1135-1138, 1980.
Jonczyk et al., “Preparation and Biological Properties of [LeuB24,LeuB25] Human Insulin,”Hoppe-Seyler's Z. Physiol. Chem. 362: 557-561, 1981.
Katsoyannis et al., “Insulin Peptides. XIX. The Synthesis of Two Nanopeptide Derivatives Related to the N Terminus of the B Chain of Insulin from Various Species (Positions 1-9),”Journal of the American Chemical Society 93(22): 5862-5864, Nov. 3, 1971.
Kristensen, C. et al., “Alanine Scanning Mutagensis of Insulin,”Journal of Biological Chemistry 272(20): 12978-12983, May 16, 1997.
Lenz et al., “Semisynthetic Des-(B27-B30)-insulins with Modified B26-Tyrosine,”Biol. Chem. Hoppe-Seyler 372: 495-504, Jul. 1991.
Leyer et al., “The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone,”Int. J. Peptide Protein Res. 46: 397-407, 1995.
Losse et al., “Synthese Eines Kondensationsfähigen Insulin-B15-20-Hexapeptidderivates,”Tetrahedron 33: 1817-1819, 1977.
Polanski et al., “Oral Administration of the Immunodominant B-chain of Insulin Reduces Diabetes in a Co-transfer Model of Diabetes in the NOD Mouse and is Associated with a Switch from Th1 to Th2 Cytokines,”Journal of Autoimmunity 10: 339-346, 1997.
Riemen et al., “Preparation of Semisynthetic Insulin Analogues from Bis(tert-butyloxycarbonyl)-desoctapeptide-insulin Phenylhydrazide Importance of the Aromatic Region B24-B26,”Biochemistry 22: 1507-1515, 1983.
Schwartz et al., “Insulin Peptides. Part XXIII. The Synthesis of a Hexadecapeptide Derivative Related to the B Chain of Human Insulin,”J. Chem. Soc. Perkin I: 2890-2894, 1973.
Schwartz and Katsoyannis, “Synthesis of Des(tetrapeptide B1-4) and Des(pentapeptide B1-5) Human Insulins. Two Biologically Active Analogues,”Biochemistry 17(21): 4550-4556, 1978.
Schwartz et al., “[12-Asparagine-B] Human Insulin,”Int. J. Peptide Protein Res. 17: 243-255, 1981.
Svoboda et al., “Semisynthetic Insulin Analogues Modified in Positions B24, B25, and B29,”Biol. Chem. Hoppe-Seyler 375:373-378, Jun. 1994.
Toyota et al., “Effects of Hexapeptide, a Compound Analogous to Insulin B Chain Fragment B-21-26(DP-432) on the Glucose Uptake into the Perfused Hind Limb of Rats,”Horm. Metab. Res. 10: 17-20, 1978.
Wang et al., “Insulin Analogues with Modifications in the β-Turn of the B-Chain,”Journal of Protein Chemistry 10(3): 313-324, 1991.
Weitzel et al., “Structure and Activity of Insulin, XVI[1-6], Semisyntheses of Desheptapeptide-(B24-30)- up to Destripeptide-(B28-30)- Insulin with Lysine or Alanine in Place of Arginine in Position B22: Influence on the Three-Step-Increase of Activity in Positions B24-B26 (Phe-Phe-Tyr),”Hoppe-Seyler's Z. Physiol. Chem. 359: 945-958, Aug. 1978.
Yueh-ting et al., “Synthesis of the Peptide Fragments of the B-Chain of Insulin,”Scientia Sincia 15(2): 221-230, 1966.
Conlon Paul J.
Gaur Amitabh
Ling Nicholas
Kam Chih-Min
Neurocrine Biosciences Inc.
Seed IP Law Group
Weber Jon
LandOfFree
Methods for treatment of diabetes using a peptide analogues... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of diabetes using a peptide analogues..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of diabetes using a peptide analogues... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3520485